How much prophylaxis is enough in haemophilia?

Area of Science:

• Haematology
• Pharmacoeconomics
• Clinical Therapeutics

Background:

• Prophylaxis is standard for severe haemophilia but high costs limit access.
• Current therapies like emicizumab are expensive, prompting research into cost-effective alternatives.
• The study addresses whether prophylaxis can be individualized, specifically for emicizumab.

Approach:

• A comprehensive literature review was conducted on haemophilia prophylaxis since the 1950s.
• The review examined various factor prophylaxis regimens and their outcomes.
• Published outcomes of low-dose emicizumab prophylaxis were also analyzed.

Key Points:

• Low-dose emicizumab provides significant patient benefits at a lower cost than standard regimens.
• Individualized prophylaxis approaches are emerging, with some non-factor therapies designed for tailored dosing.
• High doses of certain investigational non-factor therapies may pose risks.

Conclusions:

• Prophylaxis is established care for severe haemophilia.
• A growing array of prophylaxis options necessitates personalized treatment strategies.
• The haemophilia community must adapt to diverse treatments, recognizing that a 'one-size-fits-all' approach is inadequate.